Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts have been accepted for presentation at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting® 2026, being held November 5 – 9, 2026 in Denver, CO. The abstracts released today can be found on the AASLD website at https://www.aasld.org/the-liver-meeting.
Covered in this story
Call it yourself
No calls on $ALGS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Aligos Therapeutics →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.